<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: AstraZeneca earnings drop, Brexit plans outlined	</title>
	<atom:link href="https://ukinvestormagazine.co.uk/astrazeneca-earnings-drop/feed/" rel="self" type="application/rss+xml" />
	<link>https://ukinvestormagazine.co.uk/astrazeneca-earnings-drop/</link>
	<description>UK Investor Magazine provides breaking financial news and investment ideas</description>
	<lastBuildDate>Thu, 14 Feb 2019 09:30:30 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
	<item>
		<title>
		By: AstraZeneca meets guidance as new medicines lead strong performance - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/astrazeneca-earnings-drop/#comment-9553</link>

		<dc:creator><![CDATA[AstraZeneca meets guidance as new medicines lead strong performance - UK Investor Magazine]]></dc:creator>
		<pubDate>Thu, 14 Feb 2019 09:30:30 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=16115#comment-9553</guid>

					<description><![CDATA[[&#8230;] October, AstraZeneca announced that its third-quarter earnings had dropped and underscored its Brexit contingency [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] October, AstraZeneca announced that its third-quarter earnings had dropped and underscored its Brexit contingency [&#8230;]</p>
]]></content:encoded>
		
			</item>
		<item>
		<title>
		By: AstraZeneca treatment for rare disease granted orphan status - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/astrazeneca-earnings-drop/#comment-9478</link>

		<dc:creator><![CDATA[AstraZeneca treatment for rare disease granted orphan status - UK Investor Magazine]]></dc:creator>
		<pubDate>Wed, 06 Feb 2019 15:34:17 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=16115#comment-9478</guid>

					<description><![CDATA[[&#8230;] The firm&#8217;s shares are currently trading down 52p or 0.91% in morning trading, dipping to 5,657p per share 06/02/19 11:06 GMT. Shore Capital analysts have reiterated their &#8216;Buy&#8217; stance on AstraZeneca stock, while Barclays Capital have reiterated their &#8216;Overweight&#8217; stance. The company are among other large and reliable British stocks who remain uncertain amid Brexit procedings. [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] The firm&#8217;s shares are currently trading down 52p or 0.91% in morning trading, dipping to 5,657p per share 06/02/19 11:06 GMT. Shore Capital analysts have reiterated their &#8216;Buy&#8217; stance on AstraZeneca stock, while Barclays Capital have reiterated their &#8216;Overweight&#8217; stance. The company are among other large and reliable British stocks who remain uncertain amid Brexit procedings. [&#8230;]</p>
]]></content:encoded>
		
			</item>
	</channel>
</rss>
